

Coding and Billing Guide

AUGUST 2026

NEED MORE INFORMATION?



VISIT: pluvicto-hcp.com/psma-positive-mcrpc/access-and-support



CALL: 1-844-638-7222



FAX: 1-844-638-7329

Indications

PLUVICTO[®] (lutetium Lu 177 vipivotide tetraxetan) is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.

PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.

HIGHLIGHTS OF IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

- PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.
- Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.
- Ensure patients increase oral fluid intake and advise them to void as often as possible to reduce bladder radiation.

Novartis has developed this resource to provide you and your office staff with general coding and reimbursement information for PLUVICTO.

Resource overview:

Executive Summary	<u>page 3</u>
General Best Practices	<u>page 4</u>
Product Details	<u>page 5</u>
Diagnosis Codes	<u>page 6</u>
Additional Important Codes	<u>page 10</u>
Sample Claim Forms	<u>page 12</u>
Completing Prior Authorizations and Appeals	<u>page 16</u>
Reasons for Denial	<u>page 19</u>
Important Safety Information	<u>page 20</u>
Getting Started With Novartis Patient Support™	<u>page 22</u>

Please note that the current information is subject to change as new coding and reimbursement information becomes available. Individual payer guidance should be reviewed before submitting a claim.

Disclaimers

This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

- Laws, regulations, and policies concerning reimbursement are complex and updated frequently
 - While Novartis Pharmaceuticals Corporation has made every effort to be current as of the issue date on this document, the information may not be as current or comprehensive when you view it
 - Similarly, all *Current Procedural Terminology* (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes are supplied for informational purposes only, and this information does not represent any statement, promise, or guarantee by Novartis about coverage, levels of reimbursement, payment, or charge
- Consult the payer organization(s) for coverage and reimbursement policies and determination processes
- Consult your internal reimbursement specialist with any reimbursement or billing questions specific to your institution
- It is the provider's responsibility to determine and submit accurate information on claims and comply with payer coverage, reimbursement, and claim submission rules
- The existence of billing codes does not guarantee coverage and payment. Novartis Pharmaceuticals Corporation does not guarantee success in obtaining reimbursement or financial assistance. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved

Coding for HCP-administered RLTs like PLUVICTO may require separate claims: one for product administration and one for the product itself.¹

Below is a list of common codes to assist with coding and reimbursement for PLUVICTO. CLICK on each topic below for additional information.

	Code	Notes
<u>HCPCS Code Level I (CPT)^{2*}</u>	79101: Radiopharmaceutical therapy, by intravenous administration	Used to report medical procedures and services under public and private health insurance programs
<u>HCPCS Code Level II³</u>	A9607	Used to identify drugs, supplies, medical procedures, and other services Radiopharmaceuticals like PLUVICTO are billed under A-codes, not J-codes
<u>NDC Numbers⁴</u>	10-digit: 0078-1217-61	Used to identify a specific drug
	11-digit: 00078-1217-61	
<u>POS Codes⁵</u>	11: Office	Used to indicate the setting in which a service was provided
	22: On-Campus Outpatient Hospital	
	49: Independent Clinic	
<u>Revenue Codes⁶</u>	0240: All inclusive ancillary, general	Used for processing product claims. Review individual payer guidance to determine the appropriate codes
	0340: Nuclear medicine, general	
	0342: Nuclear medicine, therapeutic	
	0344: Nuclear medicine, therapeutic radiopharmaceuticals	
	0636: Pharmacy, drugs requiring detailed coding	
<u>JZ Modifier⁷</u>	Zero drug amount discarded/not administered to any patient [†]	Applied to drugs payable under Medicare Part B that are described as a "single-dose" container or "single-use" package
<u>JW Modifier⁷</u>	Drug amount discarded/not administered to any patient [†]	

HCP, health care provider; NDC, National Drug Code; POS, Place of Service; RLT, radioligand therapy.

*Separate coding for the administration of therapy may be required under different CPT codes.

[†]Contact the health plan for questions about utilizing JZ/JW modifiers.

Please see Important Safety Information on pages 20 and 21.

Please see full [Prescribing Information](#).

Appropriate reimbursement for the administration of PLUVICTO depends on accurate coding and documentation. The following information is designed to provide important tips to consider when filing a claim for PLUVICTO.

Please note that the Prostate Cancer Working Group 4 has updated the terminology for "hormone-sensitive," "castrate-sensitive," and "castration-resistant" in favor of the following:

- **mHSPC = mAPMN/S (metastatic androgen pathway modulation-naïve or -sensitive)**
- **mCRPC = mAPMR (metastatic androgen pathway modulation-resistant)**

It's important to note that these terms may be used interchangeably until the updated terminology is broadly adopted in medical practice and included in payer policies. For more information, click [here](#).

- ✓ Depending on your plan, reach out to your payer for any questions on utilizing JZ/JW modifiers
- ✓ Verify patient information (eg, name, address, member ID)
- ✓ Use the most appropriate codes to report the patient's diagnosis and care (eg, ICD-10-CM codes, CPT codes)
- ✓ Review the number of units of PLUVICTO administered
- ✓ Ensure medical record information includes appropriate documentation to support diagnosis and associated services. These may include the following:
 - Specific diagnosis for prostate cancer, including hormone-sensitive or castration-resistant disease status
 - Histology to support diagnosis of prostate cancer and disease state
 - Treatment-naïve or minimally treated with ADT and/or ARPI
 - Relevant prior imaging documentation (eg, PSMA-positive PET/CT scans)
 - Laboratory and clinical documentation supporting disease state (ie, testosterone levels, PSA trends)
 - Documentation requirements may vary based on disease state (hormone-sensitive vs castration-resistant prostate cancer). Providers should consult individual payer policies for diagnosis-specific criteria
- ✓ Recheck place of service (POS) and revenue codes
- ✓ Recheck claim prior to submission to ensure patient and coding information are accurate
- ✓ File claim in a timely manner
- ✓ Complete a PA form if required by payer
- ✓ Make sure to include CPT code 79101 (a separate PA may be required for CPT code 79101 Radiopharmaceutical therapy, by intravenous administration. Consult the payer directly for more information)
- ✓ File an appeal if PA is denied

Individual payer guidance should be reviewed before submission of a claim. Consult with the payer for any other required documentation specific to your patient, as needed.

**For any questions and additional support,
visit pluvicto-hcp.com/psma-positive-mcrpc/access-and-support
or call 1-844-638-7222.**

ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibition; CT, computed tomography; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification; ID, identification; mHSPC, metastatic hormone-sensitive prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; PA, prior authorization; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen.

**Please see Important Safety Information on pages 20 and 21.
Please see full [Prescribing Information](#).**



The following key details about PLUVICTO are included to provide context concerning patient access, coding, and reimbursement.⁴



Indications

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.

PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.



Patient Selection

Select patients with treatment-naïve or minimally treated mHSPC* as defined through inclusion/exclusion criteria and who are candidates for hormonal therapy. Additional selection criteria were used in the PSMAddition study.



Dosage and Administration[†]

The recommended dosage is 7.4 GBq (200 mCi) intravenously every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity.



Product Overview

NDC: 0078-1217-61

Single-dose vial: Single-dose vial containing 1000 MBq/mL (27 mCi/mL) of a clear and colorless to slightly yellow solution for intravenous use.

Prefilled syringe: 20-mL prefilled syringe that contains a full dose calibrated for injection on a specific day and time for each individual patient.



Storage and Handling

Store below 30°C (86°F). Do not freeze. Store in the original package to protect from ionizing radiation (lead shielding). Store PLUVICTO in accordance with local and federal laws on radioactive materials. Do not use PLUVICTO after the expiration date and time, which are stated on the label.

GBq, gigabecquerel; MBq, megabecquerel; mCi, millicurie.

*No systemic treatment was allowed, apart from ADT in the neo-/adjuvant setting and/or up to 45 days of ADT, ARPI, or both for metastatic disease prior to study enrollment.

[†]Please refer to the full Prescribing Information for complete information on dosage and administration, including safe handling of radiopharmaceuticals and dose modifications for adverse reactions.

Please see Important Safety Information on pages 20 and 21.

Please see full [Prescribing Information](#).

Diagnosis codes identify why a patient may need treatment (eg, conditions, diseases, related health problems, abnormal findings) and document the medical necessity for a patient to receive treatment with PLUVICTO.

You should review the payer's guidance to ensure appropriate codes are selected based on the patient's medical record.

When reporting ICD-10-CM codes, it is recommended to **code to the highest level of specificity to avoid denials.**

Primary Diagnosis Code

ICD-10-CM code ⁸	Description ⁸
C61	Malignant neoplasm of prostate

Secondary Diagnosis Codes

ICD-10-CM codes ⁸	Description ⁸
C63	Malignant neoplasm of other and unspecified male genital organs
C69.90	Malignant neoplasm of unspecified site of unspecified eye
C77	Secondary and unspecified malignant neoplasm of lymph nodes
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified

Secondary Diagnosis Codes (continued)

ICD-10-CM codes ⁸	Description ⁸
C78	Secondary malignant neoplasm of respiratory and digestive organs
C78.0	Secondary malignant neoplasm of lung
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.1	Secondary malignant neoplasm of mediastinum
C78.2	Secondary malignant neoplasm of pleura
C78.3	Secondary malignant neoplasm of other and unspecified respiratory organs
C78.30	Secondary malignant neoplasm of unspecified respiratory organ
C78.39	Secondary malignant neoplasm of other respiratory organs
C78.4	Secondary malignant neoplasm of small intestine
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.8	Secondary malignant neoplasm of other and unspecified digestive organs

Secondary Diagnosis Codes (continued)

ICD-10-CM codes ⁸	Description ⁸
C78 (continued)	Secondary malignant neoplasm of respiratory and digestive organs
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C78.89	Secondary malignant neoplasm of other digestive organs
C79	Secondary malignant neoplasm of other and unspecified sites
C79.0	Secondary malignant neoplasm of kidney and renal pelvis
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis
C79.1	Secondary malignant neoplasm of bladder and other and unspecified urinary organs
C79.10	Secondary malignant neoplasm of unspecified urinary organs
C79.11	Secondary malignant neoplasm of bladder
C79.19	Secondary malignant neoplasm of other urinary organs
C79.2	Secondary malignant neoplasm of skin
C79.3	Secondary malignant neoplasm of brain and cerebral meninges
C79.31	Secondary malignant neoplasm of brain
C79.32	Secondary malignant neoplasm of cerebral meninges
C79.4	Secondary malignant neoplasm of other and unspecified parts of nervous system

Secondary Diagnosis Codes (continued)

ICD-10-CM codes ⁸	Description ⁸
C79 (continued)	Secondary malignant neoplasm of other and unspecified sites
C79.40	Secondary malignant neoplasm of unspecified part of nervous system
C79.49	Secondary malignant neoplasm of other parts of nervous system
C79.5	Secondary malignant neoplasm of bone and bone marrow
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C79.7	Secondary malignant neoplasm of adrenal gland
C79.70	Secondary malignant neoplasm of unspecified adrenal gland
C79.71	Secondary malignant neoplasm of right adrenal gland
C79.72	Secondary malignant neoplasm of left adrenal gland
C79.8	Secondary malignant neoplasm of other specified sites
C79.81	Secondary malignant neoplasm of breast
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
C79.9	Secondary malignant neoplasm of unspecified site
R97.21	Rising PSA following treatment for malignant neoplasm of prostate
Z19.1*	Hormone-sensitive malignancy status
Z19.2†	Hormone-resistant malignancy status

*Use code Z19.1 for mHSPC.

†Use code Z19.2 for mCRPC.

Please see Important Safety Information on pages 20 and 21.
Please see full [Prescribing Information](#).

Healthcare Common Procedure Coding System (HCPCS) Codes

HCPCS Level II codes are used to identify drugs, supplies, medical procedures, and other services. Payers may also require the National Drug Code. HCPs should contact third-party payers for specific information on their coding, coverage, and payment policies.

HCPCS Level II code ³	Descriptor ³	Dosage ^{3*}	Maximum allowable billing units ³
A9607	Lutetium Lu 177 vipivotide tetraxetan, therapeutic, 1 mCi	200 mCi	200 mCi = 200 billing units [†]

*160 mCi for dose modification for PLUVICTO.

†1 unit is the lowest billable unit.

CMS regulations have expressly prohibited billing for overfill, which is any amount of drug greater than the amount identified on the package or label.⁷

Modifiers

JZ and JW modifiers should be applied to drugs payable under Medicare Part B that are described as a “single-dose” container or “single-use” package. HCPs and suppliers are required to report the JZ modifier when billing for drugs from single-dose containers when there are no discarded amounts. The JW modifier will still be required to report if any amount of the drug is discarded.

Modifier ^{7‡}	Description ⁷
JZ	Zero drug amount discarded/not administered to any patient
JW	Drug amount discarded/not administered to any patient

‡Contact the health plan for questions about utilizing JZ/JW modifiers.

The JW modifier must not be used to report discarded amounts of overfill.

National Drug Code (NDC)

Some payers require an NDC, which is a 10- to 11-digit code used to identify a specific drug, such as PLUVICTO, in order to process claims.

10-digit NDC ⁴	11-digit NDC ⁴	Description ⁴
0078-1217-61	00078-1217-61	Lutetium Lu 177 vipivotide tetraxetan

Current Procedural Terminology (CPT®) Code

CPT codes are the most widely accepted codes for reporting medical procedures and services under public and private health insurance programs. Below is the applicable code that relates to the administration of PLUVICTO.

Service ²	Code ²	Description ²
Administration of PLUVICTO	79101	Radiopharmaceutical therapy, by intravenous administration

CMS, Centers for Medicare & Medicaid Services.

Current Procedural Terminology (CPT) is © 2026, American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. The American Medical Association assumes no liability for data contained or not contained herein.

Please see Important Safety Information on pages 20 and 21.
Please see full [Prescribing Information](#).



Place of Service (POS) Codes

POS codes are used to indicate the setting in which a service was provided. CMS maintains a database of POS codes commonly used in the health care industry. Below are POS codes you may use. Review the full listing of the POS codes on the CMS website and consult your payer's guidance to determine the correct code for your institution.

Service ⁵	Code ⁵	Description ⁵
Office	11	Location, other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, state or local public health clinic, or intermediate care facility (ICF), where the HCP provides health examinations, diagnosis, and treatment on an ambulatory basis.
On Campus- Outpatient Hospital	22	A portion of a hospital's main campus that provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization.
Independent Clinic*	49	Location, not part of a hospital or covered facility and not described by any other POS code, that is organized and operated to provide preventive, diagnostic, therapeutic, rehabilitative, or palliative services to outpatients only.

Revenue Codes

Specific forms, such as the UB-04 (CMS-1450), require documentation of revenue codes associated with services provided to patients.

Below are commonly used revenue codes for processing claims for products such as PLUVICTO. This is not an all-inclusive list of revenue codes that could be used, and it is recommended to review individual payer guidance to determine the appropriate codes for PLUVICTO.

Code ⁶	Description ⁶
0240	All inclusive ancillary, general
0340	Nuclear medicine, general
0342	Nuclear medicine, therapeutic
0344	Nuclear medicine, therapeutic radiopharmaceuticals
0636	Pharmacy, drugs requiring detailed coding

*An independent diagnostic testing facility shall not be allowed to bill for any CPT or HCPCS codes that are solely therapeutic.

Use the following section as an example of how to complete forms (print or electronic) associated with health insurance claims for PLUVICTO.

General information is provided for each form along with annotated thumbnails to visually identify key sections.

Reminder: The sample claim forms in this section are provided for illustrative purposes only and their use is not a guarantee of reimbursement. It is your responsibility to determine the appropriate codes and submit true and correct claims for the products and services rendered. Contact payers directly for specific information on their coding requirements, coverage policies, payment policies, and fee schedules, if needed.

CMS-1500 Claim Form⁹

The CMS-1500 form is a standard Medicare claim form used by HCPs for the administration of PLUVICTO in the HCP office setting.

Key components of this form are described below and illustrated on the sample form on the following page.

Section	
Item 21	Enter the appropriate primary and secondary diagnosis codes (eg, relevant ICD-10-CM codes)
Item 23	Enter the prior authorization number, if applicable
Item 24A	List the date of service in the non-shaded area. In the shaded area, enter the N4 indicator, then the 11-digit NDC, followed by the unit of measurement and quantity. Do not include dashes. The NDC unit of measure code for PLUVICTO is likely ML (for liquids, solutions, or suspensions). ⁴ Verify with the payer for specific formatting guidelines. Example: N400078121761ML7.4
Item 24B	Enter the appropriate Place of Service (POS) code to indicate the setting where a service was provided
Item 24D	Enter the appropriate HCPCS code, A9607, for PLUVICTO use as required by the payer. ³ The HCPCS code must be accompanied by the JZ or JW modifier.* Include the appropriate CPT code to report the administration procedure, 79101 ³
Item 24E	Enter the diagnosis code reference letter as shown in Item 21 to relate the date of service and the procedures performed to the primary diagnosis. If there is more than one diagnosis required for a procedure code, only reference one letter from Item 21
Item 24G	Include the appropriate number of billing units for PLUVICTO: 200 mCi=200 billing units [†] and 1 unit for the administration procedure

*Contact the health plan for questions about utilizing JZ/JW modifiers.

[†]1 unit is the lowest billable unit.



Sample CMS-1500 Claim Form⁹

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE ☐ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN ☐ FECA BOX/LUNG ☐ OTHER ☐ 1a. INSURED'S I.D. NUMBER (For Program in Item 1)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial) 3. PATIENT'S BIRTH DATE MM DD YY SEX M ☐ F ☐ 4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street) 6. PATIENT RELATIONSHIP TO INSURED Self ☐ Spouse ☐ Child ☐ Other ☐ 7. INSURED'S ADDRESS (No., Street)

CITY STATE 8. RESERVED FOR NUCC USE CITY STATE

ZIP CODE TELEPHONE (Include Area Code) ZIP CODE TELEPHONE (Include Area Code)

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial) 10. IS PATIENT'S CONDITION RELATED TO: 11. INSURED'S POLICY GROUP OR FECA NUMBER

a. OTHER INSURED'S POLICY OR GROUP NUMBER a. EMPLOYMENT? (Current or Previous) YES ☐ NO ☐ a. INSURED'S DATE OF BIRTH MM DD YY SEX M ☐ F ☐

b. RESERVED FOR NUCC USE b. AUTO ACCIDENT? YES ☐ NO ☐ PLACE (State) b. OTHER CLAIM ID (Designated by NUCC)

c. RESERVED FOR NUCC USE c. OTHER ACCIDENT? YES ☐ NO ☐ c. INSURANCE PLAN NAME OR PROGRAM NAME

d. INSURANCE PLAN NAME OR PROGRAM NAME 10d. CLAIM CODES (Designated by NUCC) d. IS THERE ANOTHER HEALTH BENEFIT PLAN? YES ☐ NO ☐ If yes, complete items 9, 9a, and 9d.

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below. 13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

SIGNED DATE SIGNED

14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (UMP) MM DD YY 15. OTHER DATE MM DD YY 16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. ICD-9-CM 17b. NPI 18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC) 20. OUTSIDE LAB? YES ☐ NO ☐ \$ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY: Relate A-L to service line below (24E) ICD-9-CM 22. RESUBMISSION CODE ORIGINAL REF. NO. 23. PRIOR AUTHORIZATION NUMBER

	24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY	24. B. PLACE OF SERVICE EMG	24. C. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) OPT-HCPCS MODIFIER	24. D. DIAGNOSIS POINTER	24. E. \$ CHARGES	24. F. OR NDC	24. G. NPI	24. H. QUAL	24. I. PROVIDER ID #
1	N400078121761ML7.4 04 01 24 04 01 24	11	A9607 JZ		200			NPI	
2	04 01 24 04 01 24	11	79101		1			NPI	
3								NPI	
4								NPI	
5								NPI	
6								NPI	

25. FEDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? (For group claims, see 10d) 28. TOTAL CHARGE \$ 29. AMOUNT PAID \$ 30. Fund for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.) 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # ()

SIGNED DATE SIGNED

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED CMB-0935-1107 For RUM 1500 (Rev. 12)

Item 21:
Diagnosis codes

Item 23:
Prior authorization number

Item 24E:
Diagnosis code reference letter

Item 24G:
Number of units

Item 24D:
HCPCS and CPT codes

Item 24B:
Place of service

Item 24A:
Date of service and NDC



UB-04 (CMS-1450) Claim Form¹⁰

The UB-04 form, also known as the CMS-1450 form, is a Medicare claim form used by institutions when PLUVICTO is administered in the inpatient or outpatient setting.

Key components of this form are described below and illustrated on the sample form on the following page.

Section	
Form Locator (FL) 42	Enter the appropriate revenue code corresponding with the HCPCS code in FL 44 (eg, 0344 Nuclear Medicine—Therapeutic Radiopharmaceutical). Then enter the appropriate revenue code corresponding with the CPT code in FL 44 (eg, 0342 Nuclear Medicine—Therapeutic)
FL 43	Enter the revenue code description and NDC. Include the N4 indicator, then the 11-digit NDC, followed by the unit of measurement and quantity. Do not include dashes. The NDC unit of measure code for PLUVICTO is likely ML (for liquids, solutions, or suspensions). ⁴ Verify with the payer for specific formatting guidelines. Example: N400078121761ML7.4
FL 44	Enter the appropriate HCPCS code, A9607, for PLUVICTO use as required by the payer. ³ The HCPCS code must be accompanied by the JZ or JW modifier.* Include the appropriate CPT code to report the administration procedure, 79101, with a description of Radiopharmaceutical therapy, by intravenous administration ²
FL 45	Enter the dates of service
FL 46	Include the appropriate number of billing units for PLUVICTO: 200 mCi=200 billing units [†] and 1 unit for the administration procedure. Some payers may refer to the actual quantity administered via FL 43
FL 63	Enter treatment authorization codes
FL 67	Enter the appropriate primary and secondary diagnosis codes (eg, relevant ICD-10-CM codes)

*Contact the health plan for questions about utilizing JZ/JW modifiers.

[†]1 unit is the lowest billable unit.

Sample Claim Forms (continued)



NEED MORE INFORMATION?
CALL 1-844-638-7222

Sample UB-04 (CMS-1450) Claim Form¹⁰

1		2		3a PAT. CNTL #		4 TYPE OF BILL	
5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM		7 THROUGH			
8 PATIENT NAME				9 PATIENT ADDRESS			
10 BIRTHDATE		11 SEX		12 DATE		13 ADMISSION	
14 TYPE		15 SRC		16 DHR		17 STAT	
18		19		20		21	
22		23		24		25	
26		27		28		29 ACCT STATE	
30		31		32		33	
34		35		36		37	
38		39		40		41	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	
822		823		824		825	
826		827		828		829	
830		831		832		833	
834		835		836		837	
838		839		840		841	
842		843		844		845	
846		847		848		849	
850		851		852		853	
854		855		856		857	
858		859		860		861	
862		863		864		865	
866		867		868		869	
870		871		872		873	
874		875		876		877	
878		879		880		881	
882		883		884		885	
886		887		888</			



Prior Authorizations (PAs)

PAs are meant to demonstrate to the payer that the health plan's specific requirements have been met or explain why PLUVICTO is the most appropriate treatment for the patient. It is important to review a payer's guidelines when completing a PA, as these requirements often differ between payers, health plans, prescribed medications, and more.

Providers should review payer-specific guidance for hormone-sensitive versus castration-resistant prostate cancer prior to submission.

Checklist for completing a PA

- ✓ Patient's name, date of birth, insurance ID number, insurance group number, and dates of service
- ✓ Patient's diagnosis and corresponding ICD-10-CM code(s), including disease status (hormone-sensitive or hormone-resistant)
- ✓ If appropriate, a list of previous therapies
- ✓ Make sure to include CPT code 79101 (a separate PA may be required for CPT code 79101: Radiopharmaceutical therapy, by intravenous administration. Consult the payer directly for more information)

It may also be necessary to include the following information at the request of the payer:

- ✓ Physician information, including name and tax ID number
- ✓ Facility information, including name and tax ID number
- ✓ Setting of care
- ✓ Date of service
- ✓ Clinical documentation supporting disease status (ie, ongoing ADT, castration status, PSA trends)
- ✓ Supporting documentation for treatment decisions, including laboratory and imaging results
- ✓ Relevant codes, specifically CPT and HCPCS, for services/products to be performed or provided
- ✓ PLUVICTO Prescribing Information

*For more information on PAs and appeals for PLUVICTO,
visit pluvicto-hcp.com/psma-positive-mcrpc/access-and-support
or call 1-844-638-7222.*



Avoid delays in treatment

Missing or incomplete information or documentation can lead to a PA being denied. Ensure all requested PA information is included, such as prior treatment history, testing history, and necessary code(s). See below for a list of benefit managers and portals for common payers.*

Some payers may require the PA be submitted through a benefit manager. Reach out to patients' specific plans for more information.

Payer	Who manages radiopharmaceutical PA?	PA portal link (HCPCS and/or CPT)
Aetna (CVS Health)	Aetna Medical Management	Availity (HCPCS only): availity.com EviCore (HCPCS and/or CPT): EviCore.com/provider
Cigna Healthcare	EviCore Healthcare	EviCore (HCPCS and CPT): EviCore.com/provider
UnitedHealthcare (UHC)	Optum Medical Benefit Management	UHC (HCPCS and CPT): uhcprovider.com
Humana	Humana Medical Benefit Management	Availity (HCPCS and/or CPT): availity.com

Note: Some PAs are managed by other Humana partners.

*This list is current as of the time of publication based on payer-provided information and is subject to change. Providers are responsible for confirming the most current PA requirements from payers.

For more information on PAs and appeals for PLUVICTO,
visit pluvicto-hcp.com/psma-positive-mcrpc/access-and-support
or call 1-844-638-7222.



Appeals

If a patient is denied coverage for PLUVICTO, it is important to first review the denial letter and understand the payer's reason for denial, which is often related to the coverage policy or clinical appropriateness. You can then explain your clinical rationale for prescribing PLUVICTO through a Letter of Appeal. This letter should address each specific reason cited in the denial letter and demonstrate why the health plan's preferred or on-formulary treatment options do not represent the most appropriate treatment for the patient.

It is also important to review the remittance advice (RA), which will indicate where the appeal should be filed, which form to use, and any specific deadlines.

Checklist for completing an appeal

- ✓ Patient's name, date of birth, insurance ID number, insurance group number, and dates of service
- ✓ Patient's diagnosis and corresponding ICD-10-CM code(s)
- ✓ Copies of relevant medical records
- ✓ Clinical support for prescribing PLUVICTO
- ✓ A list of previous therapies, their duration, and explanation for discontinuation
- ✓ A Letter of Medical Necessity and the US Food and Drug Administration approval letter for PLUVICTO

It may also be necessary to include the following information at the request of the payer:

- ✓ Reference number of existing claim decision, if applicable
- ✓ Patient authorization and Notice of Release of Information
- ✓ Denial information, including the denial letter or RA notification
- ✓ Other supporting documentation, such as chart notes, current medications, and laboratory results

*For more information on PAs and appeals for PLUVICTO,
visit pluvicto-hcp.com/psma-positive-mcrpc/access-and-support
or call 1-844-638-7222.*

If a payer chooses to deny coverage for PLUVICTO, a letter will be sent to the HCP explaining the rationale. These letters include claim adjustment reason codes (CARCs), which describe why a claim or service line was denied or paid differently than it was billed.¹¹ Typically, a payer denial for PLUVICTO is related to the payer's coverage policy or a perceived lack of evidence of clinical appropriateness. This list is not comprehensive.

CARC ¹¹	Explanation ¹¹	Considerations for PLUVICTO
16 Administrative/ missing information denials	Claim/service lacks information or has submission/ billing error(s)	Missing or invalid NDC, malformed drug segment, missing units, or other required claim elements. ¹¹ Check accompanying RARC for specifics
18 Duplicate claim/ service	Exact duplicate claim/service	Resubmission/correction submitted as a new claim, split billing without proper replacement claim indicators, or duplicate line items (Use only with Group Code OA except where state workers' compensation regulations require CO) ^{11,12}
50 Medical necessity/ diagnosis support	These are non-covered services because this is not deemed a "medical necessity" by the payer	Denial tied to clinical criteria/ documentation gaps ¹¹ (eg, PSMA- positive PET requirement, mCRPC status, prior ARPI ± taxane/'delay taxane' rationale)
57 Dose/units not supported	Payment denied/reduced because the payer deems the information submitted does not support this level of service, this many services, this length of service, this dosage, or this day's supply	Often triggered by A9607 unit errors (not aligning to mCi), exceeding per- dose/per-course limits, or mismatch with documented administered dose ^{3,11} (eg, ~200 mCi Q6W)
151 Quantity/MUE/units denials	Payment adjusted because the payer deems the information submitted does not support this many services or units	Units exceed payer MUE, incorrect reporting of 200 mCi dose, or system dose-count edits. ^{4,11} This can also mean too many visits ¹¹
197 Prior authorization/ certification denials	Precertification/authorization/notification absent	No PA on file for commercial or Medicare Advantage, or PA not linked to claim ¹¹

MUE, medically unlikely edit; Q6W, every 6 weeks; RARC, remittance advice remark code.



Search a full list of possible [CARCs¹¹](#)



After receiving a denial letter, the HCP
can respond through a Letter of Appeal



Indications

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.

PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.

IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

- PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.
- Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.
- Ensure patients increase oral fluid intake and advise them to void as often as possible to reduce bladder radiation.
- To minimize radiation exposure to others, advise patients to limit close contact (less than 3 feet) with others for 2 days or with children and pregnant women for 7 days, to refrain from sexual activity for 7 days, and to sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days.

Myelosuppression

- PLUVICTO can cause severe and life-threatening myelosuppression. In clinical trials (PSMAddition, PSMAfore, VISION) grade 3 or 4 decreased hemoglobin (ranged from 4.3-15%), decreased leukocytes (4.4-7%), decreased neutrophils (3.5-4.5%), and decreased platelets (1.1-9%) occurred in patients treated with PLUVICTO. 5 myelosuppression-related deaths have occurred, including one due to bone marrow failure during long-term follow-up.
- Perform complete blood counts before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity of myelosuppression.

Renal Toxicity

- PLUVICTO can cause severe renal toxicity. In clinical trials grade 3 or 4 acute kidney injury (ranged from 1.3-3.4%) occurred in patients treated with PLUVICTO.
- Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Perform kidney function laboratory tests, including serum creatinine and calculated creatinine clearance (CrCl), before and during treatment. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity of renal toxicity.



IMPORTANT SAFETY INFORMATION (continued)

Embryo-Fetal Toxicity

- The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from PLUVICTO, can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose.

Infertility

- The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a radiation-absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility.

Adverse Reactions and Laboratory Abnormalities

- In the pooled safety population for the PSMAAddition, PSMAfore and VISION studies (N=1320), the most common ($\geq 20\%$) adverse reactions, including laboratory abnormalities, were decreased lymphocytes (86%), decreased hemoglobin (68%), fatigue (51%), dry mouth (46%), decreased neutrophils (35%), nausea (35%), decreased platelets (33%), decreased estimated glomerular filtration rate (28%), increased aspartate aminotransferase (25%), decreased sodium (22%), increased magnesium (22%), increased potassium (21%), decreased calcium (21%), and increased alkaline phosphatase (20%).

Novartis Patient Support is a comprehensive program that is designed to help your patients start, stay, and save on PLUVICTO.

After enrollment, Novartis Patient Support can assist with:



Benefits investigation

Once you've enrolled your patients in Novartis Patient Support, our team will conduct a benefits investigation to better understand your patients' coverage.



Prior authorization information

We'll help support your practice through the prior authorization and appeals processes to help you navigate access to PLUVICTO treatment.



Understanding access

Use Access Genius to understand current local market trends for optimal patient engagement.

Financial Support

Co-pay savings* are available for patients with private insurance

We help make PLUVICTO treatment more affordable for your eligible patients through co-pay savings.

Co-pay savings start with enrollment

Eligible patients are considered for co-pay savings when they enroll in Novartis Patient Support. Ensure that patients have completed and signed the Enrollment Form for Novartis Patient Support to activate eligibility assessment.

To complete and submit an Enrollment Form, visit pluvicto-hcp.com/psma-positive-mcrpc/access-and-support or call us at **1-844-638-7222**.

Additional financial support may be available for patients without private insurance

To find out if patients are eligible for PLUVICTO treatment through other financial support, call Novartis Patient Support at **1-844-638-7222**, Monday through Friday, 8 AM to 8 PM ET.

*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare or any other federal or state program. Offer subject to a maximum benefit per course of treatment. See complete Terms and Conditions in the Enrollment Forms for details.

References: 1. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS). Accessed April 3, 2026. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system> 2. Buy and Bill. Radiopharmaceutical Therapy - 79101 - Code and Cost Information. Accessed April 3, 2026. <https://buyandbill.com/radiopharmaceutical-therapy-79101/> 3. Centers for Medicare & Medicaid Services. CMS HCPCS Application Summaries and Coding Recommendations: Second Quarter, 2022 HCPCS Coding Cycle. Accessed April 3, 2026. <https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-2-2022-drugs-and-biologicals-updated-07192022.pdf> 4. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 5. Centers for Medicare & Medicaid Services. Place of service codes for professional claims. Accessed April 3, 2026. <https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched/downloads/website-pos-database.pdf> 6. Noridian Healthcare Solutions. Revenue codes. Accessed April 3, 2026. <https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes> 7. Centers for Medicare & Medicaid Services. Discarded drugs and biologicals—JW modifier and JZ modifier policy: Frequently asked questions. Accessed April 3, 2026. <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf> 8. Centers for Medicare and Medicaid Services. ICD-10-CM. Accessed April 3, 2026. <https://www.cms.gov/medicare/coding-billing/icd-10-codes> 9. Centers for Medicare & Medicaid Services. Professional paper claim form (CMS-1500). Accessed November 19, 2025. <https://www.cms.gov/medicare/coding-billing/electronic-billing/professional-paper-claim-form> 10. Centers for Medicare & Medicaid Services. Institutional paper claim form (CMS-1450). Accessed November 19, 2025. <https://www.cms.gov/medicare/coding-billing/electronic-billing/institutional-paper-claim-form> 11. X12. Claim adjustment reason codes. Updated November 1, 2025. Accessed April 3, 2026. <https://x12.org/codes/claim-adjustment-reason-codes> 12. Centers for Medicare & Medicaid Services. Updates for split or shared evaluation & management visits. Published May 3, 2024. Accessed May 5, 2026. <https://www.cms.gov/files/document/mm13592-updates-split-or-shared-evaluation-management-visits.pdf>

Please see Important Safety Information on pages 20 and 21.

Please see full [Prescribing Information](#).

